SCHEMBL904452

SCHEMBL904452

Nc1ccc(N2CCOCC2)cc1N

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LGMN Q99538 4/20 0.73
MAPT P10636 5/20 0.51
ALOX15 P16050 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
TP53 P04637 2/20 0.51
HTT P42858 4/20 0.50
ALDH1A1 P00352 4/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
LMNA P02545 3/20 0.50
CYP1A2 P05177 1/20 0.50
KDM4E B2RXH2 3/20 0.48
MAPK1 P28482 2/20 0.48
HSD17B10 Q99714 2/20 0.48
USP2 O75604 1/20 0.48
PRKDC P78527 4/20 0.47
PIK3CD O00329 2/20 0.47
PIK3CA P42336 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL7800602 0.90 LGMN (0.61) LGMNMAPTALOX15SMN1; SMN2NPC1
SCHEMBL16053964 0.87 LGMN (0.62) LGMNMAPTALOX15SMN1; SMN2NPC1
SCHEMBL16054633 0.86 LGMN (0.57) LGMNMAPTALOX15SMN1; SMN2NPC1
SCHEMBL22716931 0.85 LGMN (1.00) LGMNMAPTALOX15SMN1; SMN2NPC1
SCHEMBL2711166 0.85 LGMN (0.74) LGMNMAPTALOX15SMN1; SMN2NPC1
SCHEMBL23122811 0.84 LGMN (0.54) LGMNMAPTALOX15SMN1; SMN2NPC1
SCHEMBL29745213 0.84 LGMN (0.54) LGMNMAPTALOX15SMN1; SMN2NPC1
SCHEMBL8060791 0.83 LGMN (0.67) LGMNMAPTALOX15SMN1; SMN2NPC1
SCHEMBL78755 0.83 LGMN (0.67) LGMNMAPTALOX15SMN1; SMN2NPC1
SCHEMBL2712193 0.83 LGMN (0.62) LGMNMAPTALOX15SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288387-B2 Napthalimide-benzimidazole hybrids as potential antitumor agents and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2012-10-16 US claimed
US-20110166346-A1 NOVEL NAPTHALIMIDE-BENZIMIDAZOLE HYBRIDS AS POTENTIAL ANTITUMOR AGENTS AND PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETIES ACT (ACT XXI OF 1860)) (IN) 2011-07-07 US claimed
WO-2009110000-A1 NOVEL NAPTHALIMIDE-BENZIMIDAZOLE HYBRIDS AS POTENTIAL ANTITUMOUR AGENTS AND PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2009-09-11 WO claimed
US-6440896-B1 FIRST DEVELOPER SOLUTION AND DISTINCT SECOND DEVELOPER SOLUTION PRODUCE DIFFERENT COLORS; COLOR STABILITY, WEAR RESISTANCE; INCORPORATING WITHIN A PROTECTIVE MEDIUM EASTMAN KODAK COMPANY 2002-08-27 US claimed
US-6197722-B1 STORAGE STABILITY; IMAGES HAVING COLOR SATURATION AND COLOR GAMUT; INK JET PRINTING; NONSMEARING EASTMAN KODAK COMPANY 2001-03-06 US claimed
US-6143693-A STORAGE STABILITY; ENABLES TO PRODUCE IMAGES HAVING COLOR SATURATION AND COLOR GAMUT, RESISTANCE TO DARK AND LIGHT FADE, RESISTANCE TO IMAGE SMEAR AND RUB-OFF, MOISTURE AND HUMIDITY RESISTANCE EASTMAN KODAK COMPANY (US) 2000-11-07 US claimed
WO-2025264724-A1 MPRO INHIBITORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-12-26 WO disclosed
US-20250214987-A1 THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2025-07-03 US disclosed
WO-2025099451-A1 NEW COMPOUNDS AND METHODS Transition Bio Limited (GB) 2025-05-15 WO disclosed
EP-4501915-A1 THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR Korea University Research and Business Foundation (KR) 2025-02-05 EP disclosed
CN-118974021-A Preparation method of thiobenzimidazole derivative and novel intermediate for same 高丽大学校产学协力团 2024-11-15 CN disclosed
CN-116217551-B Substituted indazole or azaindazole compounds and application thereof 河南中医药大学 2024-07-30 CN disclosed
CN-117886798-A Substituted benzimidazoles and use thereof 河南中医药大学 2024-04-16 CN disclosed
WO-2002020500-A2 MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT ICOS CORPORATION (US) 2002-03-14 WO disclosed
US-20020009677-A1 Color photographic element comprising a common chromogenic coupler SZAJEWSKI RICHARD P (US) 2002-01-24 US disclosed
WO-2001096948-A2 A COLOR PHOTOGRAPHIC ELEMENT COMPRISING A COMMON CHROMOGENIC COUPLER EASTMAN KODAK COMPANY (US) 2001-12-20 WO disclosed
US-6197722-B1 STORAGE STABILITY; IMAGES HAVING COLOR SATURATION AND COLOR GAMUT; INK JET PRINTING; NONSMEARING EASTMAN KODAK COMPANY 2001-03-06 US disclosed
US-6143693-A STORAGE STABILITY; ENABLES TO PRODUCE IMAGES HAVING COLOR SATURATION AND COLOR GAMUT, RESISTANCE TO DARK AND LIGHT FADE, RESISTANCE TO IMAGE SMEAR AND RUB-OFF, MOISTURE AND HUMIDITY RESISTANCE EASTMAN KODAK COMPANY (US) 2000-11-07 US disclosed
EP-0912160-A2 OXIDATION DYES Hans Schwarzkopf GmbH & Co. KG (DE) 1999-05-06 EP disclosed
WO-1998001106-A2 OXIDATION DYES HANS SCHWARZKOPF GMBH & CO. KG (DE) 1998-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214987-A1 THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR WEE1, WEE2, HADHB LGMN 2418/4885MAPT 4632/4885ALOX15 828/4885
US-20110166346-A1 NOVEL NAPTHALIMIDE-BENZIMIDAZOLE HYBRIDS AS POTENTIAL ANTITUMOR AGENTS AND PROCESS FOR THE PREPARATION THEREOF NAP1L4, NAP1L1, CCNI LGMN 4518/4885MAPT 3299/4885ALOX15 2968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.